Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloablative Allogeneic HCT for Hematological Diseases
NCT03314974Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Hematopoietic Stem Cell Transplantation (Medical College of Wisconsin) in acute leukemia, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoma, chronic myelogenous leukemia (CML), sponsored by Masonic Cancer Center. Started Mar 2018; status: recruiting.
02
Drugs
Hematopoietic Stem Cell Transplantation (Medical College of Wisconsin)
03
Conditions
acute leukemiaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)lymphomachronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT03314974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314974.